臨床外科70巻5号

2015年05月発行

特集 外科医が知っておくべき がん薬物療法の副作用とその対策

症状別対策マニュアル

肝障害

著者： 加藤厚¹ 清水宏明¹ 大塚将之¹ 吉富秀幸¹ 古川勝規¹ 高屋敷吏¹ 久保木知¹ 高野重紹¹ 岡村大樹¹ 鈴木大亮¹ 酒井望¹ 賀川真吾¹ 宮崎勝¹

所属機関： ¹千葉大学大学院医学研究院臓器制御外科学

ページ範囲：P.570 - P.576

文献概要

【ポイント】
◆肝臓は抗がん剤の代謝に関連する主要な臓器であり，さまざまな抗がん剤またはその代謝産物により肝障害が引き起こされる．
◆薬物性肝障害に特徴的な症状はないため，使用される抗がん剤における肝障害の特徴を理解するとともに，血液検査による定期的な経過観察を行う．
◆肝臓専門医との連携を強化し，適切なタイミングで専門医による治療を開始することで重篤化を阻止することが重要である．
◆化学療法後の肝切除に際し，脂肪肝炎，類洞閉塞症候群などの肝障害を理解し，適正な化学療法施行期間，肝切除までの休薬期間，肝予備能に応じた肝切除術式を選択することが必要である．

参考文献

1）重篤副作用疾患別対応マニュアル．薬物性肝障害．平成20年4月厚生労働省［http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1i01.pdf］

2）須藤チエ，前川京子，瀬川勝智，他：医薬品副作用症例報告からみる薬物性肝障害の最近の動向．Bull Natl Inst Health Sci 130：66-70, 2012

3）van Outryve S, Schrijvers D, van den Brande J, et al：Methotrexate-associated liver toxicity in a patient with breast cancer：case report and literature review. Neth J Med 60：216-222, 2002

4）Saif MW, Shahrokni A, Cornfeld D：Gemcitabine-induced liver fibrosis in a patient with pancreatic cancer. JOP 8：460-467, 2007

5）Rubbia-Brandt L, Audard V, Sartoretti P, et al：Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15：460-466, 2004

6）Overman MJ, Maru DM, Charnsangavej C, et al：Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28：2549-2555, 2010

7）Fernandez FG, Ritter J, Goodwin JW, et al：Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200：845-853, 2005

8）Rezvani AR, McCune JS, Storer BE, et al：Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation：pharmacokinetics and clinical outcomes. Biol Blood Marrow Transplant 19：1033-1039, 2013

9）Shah RR, Morganroth J, Shah DR：Hepatotoxicity of tyrosine kinase inhibitors：clinical and regulatory perspectives. Drug Saf 36：491-503, 2013

10）Ogasawara S, Kanai F, Obi S, et al：Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int 5：850-856, 2011

11）Murata Y, Ogawa Y, Saibara T, et al：Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 7：1299-1304, 2000

12）Oien KA, Moffat D, Curry GW, et al：Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 353：36-37, 1999

13）Law CH, Tandan VR：The association between tamoxifen and the development of hepatocellular carcinoma：case report and literature review. Can J Surg 42：211-214, 1999

14）滝川　一，恩地森一，高森頼雪，他：DDW-J 2004ワークショップ薬物性肝障害診断基準の提案．肝臓46：85-90, 2005

15）Bismuth H, Adam R, Lévi F, et al：Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224：509-520, 1996

16）Nakano H, Oussoultzoglou E, Rosso E, et al：Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247：118-124, 2008

17）Nordlinger B, Sorbye H, Glimelius B, et al：Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer（EORTC Intergroup trial 40983）：a randomised controlled trial. Lancet 371：1007-1016, 2008

18）Karoui M, Penna C, Amin-Hashem M, et al：Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243：1-7, 2006

19）Aloia T, Sebagh M, Plasse M, et al：Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24：4983-4990, 2006

20）de Gramont A, Figer A, Seymour M, et al：Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18：2938-2947, 2000

21）Kooby DA, Fong Y, Suriawinata A, et al：Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7：1034-1044, 2003

22）Vauthey JN, Pawlik TM, Ribero D, et al：Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24：2065-2072, 2006

23）Van Cutsem E, Rivera F, Berry S, et al：Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer：the BEAT study. Ann Oncol 20：1842-1847, 2009

24）Reddy SK, Morse MA, Hurwitz HI, et al：Addition of bevacizumab to irinotecan-and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206：96-106, 2008

25）Ribero D, Wang H, Donadon M, et al：Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110：2761-2767, 2007